ChartRow logo
URGN
$33.91-0.38%
as of close, Oct 27, 2026
☾ AH $33.91 -0.38%
PeersMRNALLYMDTUNHJNJTMO
Share this page

UroGen Pharma Ltd. trailing returns

How UroGen Pharma Ltd. (URGN) has performed over the last day, week, month and year, over 5 years, and since inception, through October 27, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-27. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day-0.4%+0.0%-0.4%—
5 days-3.1%+0.0%-3.1%-4.4%Oct 27
1 month-18.0%+0.0%-18.0%-20.7%Oct 27
YTD+44.8%+0.0%+44.8%-32.6%Oct 27
1 year+62.6%+0.0%+62.6%-42.2%Mar 2026
5 years+15.8%+0.0%+15.8%+108.4%-82.6%May 2025
Since inception (2017)+9.8%+0.0%+9.8%+142.6%-94.0%May 2025

Growth of URGN#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+15.8%/year · +108.4%
  • Since inception (2017)+9.8%/year · +142.6%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-27). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in URGN's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is UroGen Pharma Ltd.'s return since inception?
Since 2017, UroGen Pharma Ltd. (URGN) has compounded at about +9.8% a year — +142.6% in total.

More on UroGen Pharma Ltd.